You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES
NEWS / PLASMA & BIOTHERAPIES / .........

PLASMA & BIOTHERAPIES - 21-04-2021

Kedrion-Kamada, Anti-COVID IG development update

Kedrion Biopharma and Kamada are forging ahead with the development of a new Anti-COVID Immunoglobulin therapy derived from the plasma of convalescent patients.

Watch today’s interview by Kamada’s CEO Amir London on LeFontiTV to learn more about the status of the project.

 

For more information please contact: [email protected]